Interferon has been clinically used in the treatment of slow hepatitis B for nearly 30 years and has benefited numerous patients. The relapse rate after discontinuation of the clinical cure is low. Over a course of up to six months to a year, there is very little drug resistance. Relapses after drug discontinuation are still treated with better efficacy. In particular, the long-term efficacy is better and none of the patients cured by interferon developed cirrhosis and hepatocellular carcinoma. This is why it is recommended that it be used as long as there are no contraindications. Now I will long-term application of interferon treatment of slow hepatitis B hundreds of cases, after 5 to 10 years of follow-up to get the following experience: 1, the relapse rate is low: to achieve clinical cure after discontinuation of drugs, relapse rate of about 10%. After relapse, there is still good efficacy; 2. The negative conversion rate of HBsAg (hepatitis B surface antigen) is as high as 20%, and the seroconversion rate of HbsAg/-HBs is 10%; 3. Interferon application program and specific methods: 1, the first choice of interferon adolescents, HBsAg (-) slow hepatitis B, HBV DNA ≤ 106, long-term use of nucleoside analogues of drug resistance or failure, for HBV DNA ≤ 106 initial use of interferon alone, for women of childbearing age who are not pregnant priority interferon (but the application of pregnancy during the prohibition). 2, interferon combination or sequential application For HBV DNA ≥ 106, two options are available: A: ALT>200u, first lamivudine 2-3 months, wait for ALT recovery and then combined interferon. B: ALT less than 150u, can be used to start the joint application (interferon plus lamivudine) 3, on the interferon course and dose Many scholars have shown that interferon efficacy and the course of treatment, and the dose is not obvious. (Common interferon) 3 million u / time subcutaneous injection, every other day, the total course of treatment for 6 months to 12 months, such as effective but has not reached the discontinuation conditions, can extend the course of treatment for six months to improve the efficacy and reduce the recurrence rate. For weight over 75 Kg, 5 million u should be applied each time. 180 μg of long-acting interferon should be injected subcutaneously once a week. The course of treatment is the same as above. For the initial treatment of interferon for 3 months in a row, no significant changes in DNA, can be combined with lamivudine can improve the efficacy. 4, for relapse after discontinuation of treatment After discontinuation of interferon, it is required to recheck liver function and HBVDNA once every 3 months, and after one year HBVDNA is still negative, it will be rechecked once every six months. When HBVDNA(+) in serum is greater than the lowest value detected, immediately apply interferon in treatment for 3-6 months, which can obtain better results (no need to wait for abnormal liver function and HBV DNA>105). After re-treatment to achieve clinical cure, no relapse cases have been seen. 5, interferon contraindications patients with cirrhosis, diabetes, hyperthyroidism, pregnant women, mental abnormalities, allergies to interferon. 6, adverse reactions Common fever: individual fever can be treated symptomatically, for hypothermia more than four weeks is recommended to stop using. Individual application after the platelet, white blood cell reduction, give symptomatic treatment (Lixin, un), can continue to apply. Requirement: During the application of interferon, the blood routine should be reviewed once a month.